Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab with Chemo-Radiotherapy in Cervical Cancer
NCT06942416Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Feb 2025
- Primary completion
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab and tuvonralimab in Cervical Cancer (CC), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-Free Survival up to 60 months. Started Feb 2025; status: recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06942416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06942416.